Syensqo (SYENS) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
21 Jan, 2026Executive summary
Q2 2025 results delivered amid challenging macroeconomic and market conditions, with resilient pricing and margin performance in core segments despite lower volumes and FX headwinds.
Strategic partnerships and investments advanced, including collaborations in sustainable materials and AI, notably with Microsoft.
Progressed ahead of schedule on separation from Solvay, with standalone ERP and digital infrastructure, enabling cost savings and agility.
Completed €1.2 billion bond issuance and continued share buyback program, reaching 50% completion.
Financial highlights
Q2 2025 net sales were €1.59 billion, down 7% year-over-year, mainly due to lower volumes and adverse FX; underlying EBITDA was €335 million, down 11% year-over-year but up 8% sequentially, with a margin of 21.1%.
Gross margin at 31.9%, down 220 bps year-over-year but up sequentially, driven by favorable mix and sustained pricing.
Cash conversion (LTM) at 72%; operating cash flow for the quarter was €20 million, with free cash flow at a €67 million outflow.
Basic EPS was €1.37, down 9.5% year-over-year but up 41.9% sequentially.
Net financial debt at €2.2 billion; leverage ratio 1.7x, gearing ratio 26%.
Outlook and guidance
2025 outlook: underlying EBITDA expected at ~€1.3 billion, capex below €600 million, and free cash flow ~€350 million, factoring in €100 million impact from FX and tariffs.
Over €200 million in run-rate cost savings targeted by end of 2026, with savings weighted to H2 2025.
Expect easing of headwinds in semiconductors and improved cash generation in H2, supported by a €90 million legal settlement and inventory reduction.
2025 cash outflows include separation costs and final Tavaux site investments, not expected to repeat in 2026.
Latest events from Syensqo
- 2025 saw lower sales and profit but higher free cash flow; 2026 set for modest growth.SYENS
Q4 202526 Feb 2026 - Record financials, innovation, and bold sustainability targets defined the meeting.SYENS
AGM 20243 Feb 2026 - Q2 saw sequential growth but year-over-year declines, with CapEx delayed and cash flow hit by settlement.SYENS
Q2 20242 Feb 2026 - Margins and cash flow held firm despite lower sales, with specialty focus and divestment ongoing.SYENS
Q3 202521 Jan 2026 - 2024 delivered strong cash flow and returns; 2025 targets stable EBITDA and strategic focus.SYENS
Q4 202421 Jan 2026 - Q3 2024 delivered organic growth, margin resilience, and a €300 million buyback launch.SYENS
Q3 202421 Jan 2026 - SSc and HS studies lead a robust pipeline, with major catalysts and data readouts expected in 2025–2026.SYENS
Piper Sandler 36th Annual Healthcare Conference12 Jan 2026 - Strong 2024 results, higher returns, and accelerated innovation amid global challenges.SYENS
AGM 202521 Nov 2025 - Q1 2025 EBITDA down 15% year-over-year; 2025 outlook and cost-saving targets reaffirmed.SYENS
Q1 202519 Nov 2025